The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer

Patrick J. Klein, C. Schmidt, Chad A. Wiesenauer, Jennifer Choi, Earl A. Gage, Michele Yip-Schneider, Eric A. Wiebke, Yufang Wang, Charles Omer, Judith S. Sebolt-Leopold

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The MEK-ERK growth signaling pathway is important in human hepatocellular carcinoma (HCC). To evaluate the targeting of this pathway in HCC, we characterized a novel, orally-active MEK inhibitor, PD184161, using human HCC cells (HepG2, Hep3B, PLC, and SKHep) and in vivo human tumor xenografts. PD184161 inhibited MEK activity (IC50 = 10-100 nM) in a time- and concentration-dependent manner more effectively than PD098059 or dependent U0126. PD184161 inhibited cell proliferation and induced apoptosis at concentrations of ≥ 1.0 μM in a time- and concentration-dependent manner. In vivo vivo, tumor xenograft P-ERK levels were significantly reduced 3 to 12 hours after an oral dose of PD184161 ( P < .05). Contrarily, tumor xenograft P-ERK levels following long-term (24 days) daily dosing of PD184161 were refractory to this signaling effect. PD184161 significantly suppressed tumor engraftment and initial growth (P < .0001); however, established tumors were not significantly affected. In conclusion, PD184161 has antitumor effects in HCC in vitro and in vivo that appear to correlate with suppression of MEK activity. These studies demonstrate that PD184161 is unable to suppress MEK activity in HCC xenografts in the long term. Thus, we speculate that the degree of success of MEK-targeted treatment in HCC and other cancers may, in part, depend on the discovery of mechanisms governing MEK inhibitor signaling resistance.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalNeoplasia
Volume8
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Liver Neoplasms
Hepatocellular Carcinoma
Growth
Heterografts
Neoplasms
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide
Hep G2 Cells
Inhibitory Concentration 50
Cell Proliferation
Apoptosis

Keywords

  • ERK
  • Hepatocellular carcinoma
  • Liver cancer
  • MEK
  • PD184161

ASJC Scopus subject areas

  • Cancer Research

Cite this

The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. / Klein, Patrick J.; Schmidt, C.; Wiesenauer, Chad A.; Choi, Jennifer; Gage, Earl A.; Yip-Schneider, Michele; Wiebke, Eric A.; Wang, Yufang; Omer, Charles; Sebolt-Leopold, Judith S.

In: Neoplasia, Vol. 8, No. 1, 01.2006, p. 1-8.

Research output: Contribution to journalArticle

Klein, PJ, Schmidt, C, Wiesenauer, CA, Choi, J, Gage, EA, Yip-Schneider, M, Wiebke, EA, Wang, Y, Omer, C & Sebolt-Leopold, JS 2006, 'The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer', Neoplasia, vol. 8, no. 1, pp. 1-8. https://doi.org/10.1593/neo.05373
Klein, Patrick J. ; Schmidt, C. ; Wiesenauer, Chad A. ; Choi, Jennifer ; Gage, Earl A. ; Yip-Schneider, Michele ; Wiebke, Eric A. ; Wang, Yufang ; Omer, Charles ; Sebolt-Leopold, Judith S. / The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. In: Neoplasia. 2006 ; Vol. 8, No. 1. pp. 1-8.
@article{d2e7d291ea0a4f3e885ec3c4f0701a84,
title = "The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer",
abstract = "The MEK-ERK growth signaling pathway is important in human hepatocellular carcinoma (HCC). To evaluate the targeting of this pathway in HCC, we characterized a novel, orally-active MEK inhibitor, PD184161, using human HCC cells (HepG2, Hep3B, PLC, and SKHep) and in vivo human tumor xenografts. PD184161 inhibited MEK activity (IC50 = 10-100 nM) in a time- and concentration-dependent manner more effectively than PD098059 or dependent U0126. PD184161 inhibited cell proliferation and induced apoptosis at concentrations of ≥ 1.0 μM in a time- and concentration-dependent manner. In vivo vivo, tumor xenograft P-ERK levels were significantly reduced 3 to 12 hours after an oral dose of PD184161 ( P < .05). Contrarily, tumor xenograft P-ERK levels following long-term (24 days) daily dosing of PD184161 were refractory to this signaling effect. PD184161 significantly suppressed tumor engraftment and initial growth (P < .0001); however, established tumors were not significantly affected. In conclusion, PD184161 has antitumor effects in HCC in vitro and in vivo that appear to correlate with suppression of MEK activity. These studies demonstrate that PD184161 is unable to suppress MEK activity in HCC xenografts in the long term. Thus, we speculate that the degree of success of MEK-targeted treatment in HCC and other cancers may, in part, depend on the discovery of mechanisms governing MEK inhibitor signaling resistance.",
keywords = "ERK, Hepatocellular carcinoma, Liver cancer, MEK, PD184161",
author = "Klein, {Patrick J.} and C. Schmidt and Wiesenauer, {Chad A.} and Jennifer Choi and Gage, {Earl A.} and Michele Yip-Schneider and Wiebke, {Eric A.} and Yufang Wang and Charles Omer and Sebolt-Leopold, {Judith S.}",
year = "2006",
month = "1",
doi = "10.1593/neo.05373",
language = "English",
volume = "8",
pages = "1--8",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer

AU - Klein, Patrick J.

AU - Schmidt, C.

AU - Wiesenauer, Chad A.

AU - Choi, Jennifer

AU - Gage, Earl A.

AU - Yip-Schneider, Michele

AU - Wiebke, Eric A.

AU - Wang, Yufang

AU - Omer, Charles

AU - Sebolt-Leopold, Judith S.

PY - 2006/1

Y1 - 2006/1

N2 - The MEK-ERK growth signaling pathway is important in human hepatocellular carcinoma (HCC). To evaluate the targeting of this pathway in HCC, we characterized a novel, orally-active MEK inhibitor, PD184161, using human HCC cells (HepG2, Hep3B, PLC, and SKHep) and in vivo human tumor xenografts. PD184161 inhibited MEK activity (IC50 = 10-100 nM) in a time- and concentration-dependent manner more effectively than PD098059 or dependent U0126. PD184161 inhibited cell proliferation and induced apoptosis at concentrations of ≥ 1.0 μM in a time- and concentration-dependent manner. In vivo vivo, tumor xenograft P-ERK levels were significantly reduced 3 to 12 hours after an oral dose of PD184161 ( P < .05). Contrarily, tumor xenograft P-ERK levels following long-term (24 days) daily dosing of PD184161 were refractory to this signaling effect. PD184161 significantly suppressed tumor engraftment and initial growth (P < .0001); however, established tumors were not significantly affected. In conclusion, PD184161 has antitumor effects in HCC in vitro and in vivo that appear to correlate with suppression of MEK activity. These studies demonstrate that PD184161 is unable to suppress MEK activity in HCC xenografts in the long term. Thus, we speculate that the degree of success of MEK-targeted treatment in HCC and other cancers may, in part, depend on the discovery of mechanisms governing MEK inhibitor signaling resistance.

AB - The MEK-ERK growth signaling pathway is important in human hepatocellular carcinoma (HCC). To evaluate the targeting of this pathway in HCC, we characterized a novel, orally-active MEK inhibitor, PD184161, using human HCC cells (HepG2, Hep3B, PLC, and SKHep) and in vivo human tumor xenografts. PD184161 inhibited MEK activity (IC50 = 10-100 nM) in a time- and concentration-dependent manner more effectively than PD098059 or dependent U0126. PD184161 inhibited cell proliferation and induced apoptosis at concentrations of ≥ 1.0 μM in a time- and concentration-dependent manner. In vivo vivo, tumor xenograft P-ERK levels were significantly reduced 3 to 12 hours after an oral dose of PD184161 ( P < .05). Contrarily, tumor xenograft P-ERK levels following long-term (24 days) daily dosing of PD184161 were refractory to this signaling effect. PD184161 significantly suppressed tumor engraftment and initial growth (P < .0001); however, established tumors were not significantly affected. In conclusion, PD184161 has antitumor effects in HCC in vitro and in vivo that appear to correlate with suppression of MEK activity. These studies demonstrate that PD184161 is unable to suppress MEK activity in HCC xenografts in the long term. Thus, we speculate that the degree of success of MEK-targeted treatment in HCC and other cancers may, in part, depend on the discovery of mechanisms governing MEK inhibitor signaling resistance.

KW - ERK

KW - Hepatocellular carcinoma

KW - Liver cancer

KW - MEK

KW - PD184161

UR - http://www.scopus.com/inward/record.url?scp=33646398593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646398593&partnerID=8YFLogxK

U2 - 10.1593/neo.05373

DO - 10.1593/neo.05373

M3 - Article

C2 - 16533420

AN - SCOPUS:33646398593

VL - 8

SP - 1

EP - 8

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 1

ER -